Schroeder Mark S., EVP, President of Diagnostics and COO of Labcorp (LH), has filed 42 Form 4 transactions with the SEC, all in a single company. The pattern is unambiguous: a complete absence of open-market purchases (zero buy value) against roughly $4.45 million in open-market sales. His trading activity is dominated by automatic and compensatory events—share withholdings to cover taxes (code F), option exercises (code M), and equity grants (code A)—rather than discretionary bets. The only true market transactions are two open-market sales, both in early 2025: $1.33 million on February 28 and $610,450 on March 28.
The recent filings, however, show no new sales. Since late March 2025, Schroeder's activity has shifted entirely to non-discretionary mechanics. On March 26, 2026, he had shares withheld to cover taxes in two separate transactions valued at $393,982 and $1.23 million, paired with zero-value grants. Earlier in February 2026, he executed a series of option exercises and tax-withholding events, with the largest withholding at $75,082 on February 11. These are routine administrative actions tied to equity compensation, not directional signals.
The data reveals a seller, not a buyer, but one whose selling is concentrated and dated. The two open-market sales in February and March 2025 account for the entire $4.45 million sell total, and no discretionary sales have occurred in over a year. The most recent activity—grants and tax withholdings—suggests a period of accumulation through compensation rather than divestment. For investors tracking insider conviction, the absence of any open-market purchases across all 42 filings is the standout fact: Schroeder has never put his own cash into LH shares during this window, even as he has periodically trimmed his position.
AI-assisted summary